Vitamin markets: Vitamin E prices stable but suppliers are eager to push prices higher

Highlights

Vitamin E 50%: Prices have stabilised recently, despite suppliers’ attempts to increase prices through strategies like reducing availability. A Western supplier is under force majeure until mid-2025.
Vitamin A 1000: After a period of price decline, the market is stable, but weak. Increased capacity from both China and a Western supplier (under force majeure until April 2025) is expected.
Vitamin D3 500: Prices remain high due to ongoing material shortages and suppliers’ firm pricing strategies. A major supplier announced another price increase, prompting buyers to secure additional volume in Q1 as prices are not expected to drop soon.
Vitamin B2 80%: The market is stable, with a slight price decline in Europe, while other regions see consistent prices.
D-Calpan: The market remains stable with low prices due to oversupply. Despite some suppliers’ attempts to increase prices, no significant changes are anticipated.
Vitamin B3: Prices have remained stable to weakish, with some slight decreases due to supplier competition.
Biotin: The market remains stable at historically low levels, with no successful price increases from suppliers.
Vitamin C 35% Mono: Suppliers are eager to raise prices but have been unsuccessful due to oversupply. The market is stable, with significant volumes contracted for Q1 and Q2

In partnership with Feed Additive Prices

Vitamin E 50%

Overall vitamin E prices have shown a degree of stability, yet suppliers are eager to push prices higher through various strategies such as announcing price increases, reducing availability, or temporarily halting offers during maintenance periods. Nevertheless, there appears to be a sufficient supply in the pipeline, as current trade transactions do not reflect the supplier’s desired price hikes. While a slight decline has been observed over the past months, prices have stabilised recently, failing to rise as suppliers had hoped. One Western supplier remains under force majeure and is not expected to resolve this situation before the summer of 2025. The first quarter is well contracted, with a small fraction of the second quarter also secured.

Vitamin A 1000

After a period of declining prices, the market now appears more stable. However, the outlook remains weak as additional capacity is anticipated to enter the market. This additional supply is expected from China, as well as from a Western supplier, which is still under force majeure. While the force majeure has been lifted for some of their aroma chemicals, the timeline indicates that the force majeure on vitamin A is expected to be resolved by April 2025. The current market is quite calm, with buyers refraining from making long-term bookings, and contracts for the first quarter are already secured.

VITAMIN PRICES: Here the market prices of 3 important vitamins are tracked – check it out…

Vitamin D3 500

The persistently high prices of vitamin D3 show no indication of decline, as material shortages continue and suppliers remain resolute in their pricing strategies. Recently, a major supplier announced yet another price increase, prompting some buyers to reconsider their initial wait-and-see approach and prepare to re-enter the market in the first quarter to secure additional volume, as they realise that a short-term price reduction is improbable, with a significant portion of the first quarter’s supply already contracted.

Vitamin B2 80%

Although manufacturers still express a desire to raise prices, the market remains stable and appears well-balanced. In Europe, a slight decline in prices has even been observed, while in other regions, prices have remained consistent for an extended period. No significant changes are anticipated in the near future, and the first quarter is now fully contracted.

D-Calpan

In all regions, the market remains quite stable regarding actual transaction prices and the market price continues to be low. While some key suppliers of d-calpan are eager to see prices rise, the prevailing oversupply has so far prevented a shift from the current pricing structure, and no significant changes are anticipated in the near future. The first quarter and part of the second quarter are already contracted.

Vitamin B3

Vitamin B3 prices have remained relatively stable on average for several months. There is a contradiction among suppliers, as some manufacturers are eager to raise prices while others prioritise acquiring or retaining market share. Recently, the market has shifted towards the latter, resulting in a slight decrease in prices across most regions. Although Q1 contracts are secured, buyers are currently hesitant to commit to Q2 volumes.

Biotin

The biotin market has remained stable for several months, continuing to hover at a historically low level. Suppliers have made multiple attempts to raise prices, yet none have succeeded thus far. Currently, the market appears balanced, and no significant changes are anticipated in the near future. Contracts for Q1 are secured, along with a portion of Q2.

Vitamin C 35% mono

The eagerness of suppliers to raise prices is evident, whether through actual price hikes or by withholding offers. Currently, the market appears to be oversupplied, as prices have not risen compared to the higher prices seen in late 2024. This situation has created a patience game between suppliers and buyers, as the market remains stable with little expected nearby change. A significant portion of Q1 and Q2 has already been contracted.